Dr Simon Chu
Research Scientist
Centre for Endocrinology and Metabolism
Hudson Institute of Medical Research
Australia
Biography
Dr. Simon Chu completed his PhD at Prince Henry’s Institute (now Hudson Institute of Medical Research) in 2005. His studies focused on the roles of the estrogen receptor in the pathogenesis of a subset of ovarian tumours, and in particular, the impact that molecular signalling pathways of the cell have on this receptor. After gaining his PhD, Dr. Chu continued his work at PHI, examining the consequences of blocking this mechanism using new therapeutic compounds to explore whether this might lead to a new chemotherapeutic approach to treating this disease.
Research Interest
Simon’s research is focused on the causes of ovarian cancer. Although ovarian tumours are generally thought to arise from the cells on the surface of the ovary, there is increasing evidence that up to three quarters of ovarian serous cancers may originate from the fimbrial epithelium at the ends of the fallopian tube, adjacent to the ovary. His focus is thus on understanding the origins of these types of ovarian cancer.
Publications
-
Lague MN, Paquet M, Fan HY, Kaartinen MJ, Chu S, Jamin SP, Behringer RR, Fuller PJ, Mitchell A, Dore M, Huneault LM, Richards JS, Boerboom D: Synergistic effects of pten loss and wnt/ctnnb1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis 2008;29:2062-2072.
-
Bilandzic M, Chu S, Farnworth PG, Harrison C, Nicholls P, Wang Y, Escalona RM, Fuller PJ, Findlay JK, Stenvers KL: Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol Endocrinol 2009;23:539-548.
-
Chu S, Alexiadis M, Fuller PJ: Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors. Reprod Sci 2009;16:397-407.
